Real-world Experience of Catheter Ablation Using CARTO Technologies for Treating Paroxysmal and Persistent Atrial Fibrillation and Ventricular Arrhythmias

What this Trial Is About

This research evaluates the real-world safety and long-term effectiveness of catheter ablation procedures in treating patients with paroxysmal atrial fibrillation PAF, persistent atrial fibrillation PsAF, and ventricular arrhythmias VA. The study is an observational, prospective, multi-center registry collecting clinical data from the use of commercially available CARTO technologies by Biosense Webster, Inc. These procedures are performed under usual care by healthcare practitioners. Participants receive catheter ablation using Biosense Websters CARTO devices such as THERMOCOOL SMARTTOUCH, QDOT MICRO, and VARIPULSE catheters. The registry includes patients with symptomatic PAF or PsAF who are candidates for ablation, as well as patients with documented ventricular arrhythmias suitable for catheter ablation. The ablations follow standard care practices at participating sites, and future new ablation technologies may also be included as they become available. Throughout the study, participants undergo routine baseline and follow-up evaluations aligned with standard care without extra visits required by the registry. Researchers monitor outcomes including procedural efficiency, acute safety within 30 days post-ablation, arrhythmia recurrence after a 90-day blanking period, and long-term effectiveness up to 12 months. Patient-reported symptoms, medication usage, and clinical scores such as CHA2DS2VASC are also collected to assess the overall impact of the ablation procedures.

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias